India's Growing Obesity Epidemic
Obesity has evolved from a concern of affluence to a nationwide public health crisis in India. The World Health Organization (WHO) reports over 1 billion people worldwide living with obesity, with prevalence surging in nearly every country. In India, the National Family Health Survey-5 (NFHS-5, 2019-21) indicates that nearly one in four adults is obese, a sharp rise driven by urbanization, dietary shifts toward processed foods, sedentary lifestyles, and genetic predispositions.
A study in The Lancet Regional Health - Southeast Asia underscores abdominal obesity—visceral fat accumulation around organs—as particularly alarming: 40% in women and 12% in men overall, escalating to 50-60% among women aged 30-49. Risk factors include older age, urban living, higher socioeconomic status, and non-vegetarian diets, but trends now extend to rural and lower-income groups, signaling a democratization of the disease.
Obesity is a chronic, relapsing disease from interactions of genetics, neurobiology, behaviors, and environment, per WHO—not merely a lifestyle failing.
Survey Insights: Perceptions and Realities of Obesity in India
A collaborative survey by The Times of India and Novo Nordisk, involving 16,741 respondents, paints a stark picture. Only 53% recognize obesity as a medical condition; 32% dismiss it as non-medical, and 15% are unsure. Yet, 6 in 10 Indians are already grappling with complications like cardiovascular disease, hormonal imbalances (e.g., PCOS), type 2 diabetes, and fatty liver.
Over 80% have attempted weight loss, often through diets or exercise, but sustained success remains elusive. Awareness of prescription options is low: just 16% are well-informed about GLP-1 RAs, while 44% have vague knowledge. This gap highlights the need for education on evidence-based treatments beyond willpower alone.
What Are GLP-1 Receptor Agonists (RAs)?
GLP-1 RAs mimic glucagon-like peptide-1 (GLP-1), an incretin hormone released from intestinal L-cells post-meal. Native GLP-1 regulates glucose homeostasis, but its short half-life (1-2 minutes) limits therapeutic use. These injectable analogs—weekly subcutaneous doses—extend action to hours or days.
In India, key options include:
- Ozempic (semaglutide): Launched December 2025 by Novo Nordisk, primarily for type 2 diabetes but used off-label for weight loss.
- Wegovy (semaglutide): Higher-dose version launched June 2025, FDA-approved specifically for obesity.
- Mounjaro (tirzepatide): Dual GLP-1/GIP agonist, launched March 2025, showing superior weight loss in trials.
These drugs target obesity as a chronic condition, complementing—not replacing—lifestyle interventions.
Mechanisms: How GLP-1 RAs Drive Weight Loss
GLP-1 RAs act via multiple pathways:
- Appetite suppression: Bind hypothalamic receptors, increasing satiety signals and reducing hunger hormones like ghrelin.
- Slowed gastric emptying: Prolongs fullness, blunts postprandial glucose spikes.
- Glucose regulation: Enhance insulin secretion (glucose-dependent), suppress glucagon, improving insulin sensitivity.
- Cardiovascular protection: Reduce inflammation, improve endothelial function.
Tirzepatide's GIP agonism adds fat metabolism benefits, explaining its edge. Clinical trials like STEP (semaglutide) show 15-17% weight loss at 68 weeks; SURMOUNT (tirzepatide) up to 21%—far surpassing lifestyle alone (2-5%).
Clinical Evidence and Dosing Considerations
For obesity (BMI ≥30 or ≥27 with comorbidities), start low to minimize side effects:
- Semaglutide (Ozempic/Wegovy): 0.25 mg weekly, titrate to 2.4 mg over 16 weeks.
- Tirzepatide (Mounjaro/Zepbound): 2.5 mg weekly, up to 15 mg.
Sustained use maintains loss; discontinuation leads to ~2/3 regain within a year. Long-term data (SELECT trial) shows 20% reduction in major cardiovascular events, even without diabetes.
